Background:Many tumors are refractory to immune checkpoint inhibitors,but their combination with cytotoxics is expected to improve sensitivity.Understanding how and when cytotoxics best re-stimulate tumor immunity cou...Background:Many tumors are refractory to immune checkpoint inhibitors,but their combination with cytotoxics is expected to improve sensitivity.Understanding how and when cytotoxics best re-stimulate tumor immunity could help overcome resistance to immune checkpoint inhibitors.Methods:In vivo studies were performed in C57BL/6 mice grafted with immune-refractory LL/2 lung cancer model.A longitudinal immunomonitoring study on tumor,spleen,and blood after multiple treatments including Cisplatin,Pemetrexed,and anti-VEGF,either alone or in combination,was performed,spanning a period of up to 21 days,to determine the optimal time window during which immune checkpoint inhibitors should be added.Finally,an efficacy study was conducted comparing the antiproliferative performance of various schedules of anti-VEGF,Pemetrexed-Cisplatin doublet,plus anti-PD-1(i.e.,immunomonitoring-guided scheduling,concurrent dosing or a random sequence),as well as single agent anti-PD1.Results:Immunomonitoring showed marked differences between treatments,organs,and time points.However,harnessing tumor immunity(i.e.,promoting CD8 T cells or increasing the T CD8/Treg ratio)started on D7 and peaked on D14 with the anti-VEGF followed by cytotoxics combination.Therefore,a 14-day delay between anti VEGF/cytotoxic and anti-PD1 administration was considered the best sequence to test.Efficacy studies then confirmed that this sequence achieved higher antiproliferative efficacy compared to other treatment modalities(i.e.,-71%in tumor volume compared to control).Conclusions:Anti-VEGF and cytotoxic agents show time-dependent immunomodulatory effects,suggesting that sequencing is a critical feature when combining these agents with immune checkpoint inhibitors.An efficacy study confirmed that sequencing treatments further enhance antiproliferative effects in lung cancer models compared to concurrent dosing and partly reverse the resistance to cytotoxics and anti-PD1.展开更多
基金supported by A^(*)midex Foundation-initiative d’Excellence and the Aix-Marseille Université。
文摘Background:Many tumors are refractory to immune checkpoint inhibitors,but their combination with cytotoxics is expected to improve sensitivity.Understanding how and when cytotoxics best re-stimulate tumor immunity could help overcome resistance to immune checkpoint inhibitors.Methods:In vivo studies were performed in C57BL/6 mice grafted with immune-refractory LL/2 lung cancer model.A longitudinal immunomonitoring study on tumor,spleen,and blood after multiple treatments including Cisplatin,Pemetrexed,and anti-VEGF,either alone or in combination,was performed,spanning a period of up to 21 days,to determine the optimal time window during which immune checkpoint inhibitors should be added.Finally,an efficacy study was conducted comparing the antiproliferative performance of various schedules of anti-VEGF,Pemetrexed-Cisplatin doublet,plus anti-PD-1(i.e.,immunomonitoring-guided scheduling,concurrent dosing or a random sequence),as well as single agent anti-PD1.Results:Immunomonitoring showed marked differences between treatments,organs,and time points.However,harnessing tumor immunity(i.e.,promoting CD8 T cells or increasing the T CD8/Treg ratio)started on D7 and peaked on D14 with the anti-VEGF followed by cytotoxics combination.Therefore,a 14-day delay between anti VEGF/cytotoxic and anti-PD1 administration was considered the best sequence to test.Efficacy studies then confirmed that this sequence achieved higher antiproliferative efficacy compared to other treatment modalities(i.e.,-71%in tumor volume compared to control).Conclusions:Anti-VEGF and cytotoxic agents show time-dependent immunomodulatory effects,suggesting that sequencing is a critical feature when combining these agents with immune checkpoint inhibitors.An efficacy study confirmed that sequencing treatments further enhance antiproliferative effects in lung cancer models compared to concurrent dosing and partly reverse the resistance to cytotoxics and anti-PD1.
